Small molecule that binds to cyclin dependent kinase inhibitor 1B (P27KIP1)

摘要

Various compounds capable of binding to the cyclin dependent kinase inhibitor 1B and pharmaceutically acceptable salts thereof are provided. The compound may have a structure according to Formula I or Formula II detailed herein. The compound may include SJ747, SJ749, SJ755, SJ757. Pharmaceutical formulations containing the compound or pharmaceutically acceptable salt are also provided along with methods of use thereof. The agents and methods may be useful for the treatment of cancer. In some embodiments, the cancer is associated with a mislocalization of the essentially disordered protein p27. In some embodiments, the cancer is resistant to anti-cancer therapy. Accordingly, the pharmaceutical formulation may include a second active agent and/or may be provided in combination with a second active agent, such as a cancer therapeutic agent. In various aspects, methods are also provided for promoting re-entry into the cell division cycle in a subject in need thereof using the compounds and agents described herein.